Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 7—July 2023
Synopsis

Nationwide Outbreak of Candida auris Infections Driven by COVID-19 Hospitalizations, Israel, 2021–20221

Roni Biran, Regev Cohen, Talya Finn, Tal Brosh-Nissimov, Galia Rahav, Dafna Yahav, Sharon Amit, Yael Shachor-Meyouhas, Alaa Atamna, Jihad Bishara, Liat Ashkenazi-Hoffnung, Haim Ben Zvi, Mirit Hershman-Sarafov, Shlomo Maayan, Yasmin Maor, Orna Schwartz, Oren Zimhony, Jonathan Lellouche, Meital Elbaz, Ela Burdelova, Naama Mizrahi, Anna Novikov, Oryan Henig, and Ronen Ben-AmiComments to Author 
Author affiliations: Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (R. Biran, M. Elbaz, E. Burdelova, N. Mizrahi, A. Novikov, O. Henig, R. Ben-Ami); Hillel Yaffe Medical Center, Hadera, Israel (R. Cohen); Technion, Haifa, Israel (R. Cohen, Y. Shachor-Meyouhas, M. Hershman-Sarafov); Sanz Medical Center, Netanya, Israel (T. Finn, J. Lellouche); Samson Assuta Ashdod University Hospital, Ashdod, Israel (T. Brosh-Nissimov); Ben Gurion University in the Negev, Beer Sheba, Israel (T. Brosh-Nissimov); Sheba Medical Center, Tel Hashomer, Israel (G. Rahav, D. Yahav, S. Amit); Tel Aviv University, Tel Aviv (G. Rahav, D. Yahav, A. Atamna, J. Bishara, L. Ashkenazi-Hoffnung, H. Ben Zvi, Y. Maor, R. Ben-Ami); Rambam Medical Center, Haifa (Y. Shachor-Meyouhas); Beilinson Hospital, Rabin Medical Center, Petach-Tikva, Israel (A. Atamna, J. Bishara); Schneider Children’s Medical Center, Petach-Tikva (L. Ashkenazi-Hoffnung); Bnai Zion Medical Center, Haifa (M. Hershman Sarafov); Barzilai Medical Center, Ashdod (S. Maayan); Hebrew University of Jerusalem, Jerusalem, Israel (S. Maayan, O. Zimhony); Wolfson Medical Center, Holon, Israel (Y. Maor, O. Schwartz); Kaplan Medical Center, Rehovot, Israel (O. Zimhony); Ariel University, Ariel, Israel (J. Lellouche).

Main Article

Figure 3

Minimum spanning trees of Candida auris strains for 2014–2020 (A) and 2014–2022 (B), Israel. Genetic relatedness of C. auris isolates was assessed using multilocus sequence typing. Strain cluster designation was determined using sequences published by Kwon et al. (shown in gray nodes) (17). Nodes are colored according to the respective medical center. Nodes marked with asterisks represent 2016 importation event from South Africa. C, clade; H, hospital; NH, nursing home.

Figure 3. Minimum spanning trees of Candida auris strains for 2014–2020 (A) and 2014–2022 (B), Israel. Genetic relatedness of C. auris isolates was assessed using multilocus sequence typing. Strain cluster designation was determined using sequences published by Kwon et al. (shown in gray nodes) (17). Nodes are colored according to the respective medical center. Nodes marked with asterisks represent 2016 importation event from South Africa. C, clade; H, hospital; NH, nursing home.

Main Article

References
  1. Du  H, Bing  J, Hu  T, Ennis  CL, Nobile  CJ, Huang  G. Candida auris: Epidemiology, biology, antifungal resistance, and virulence. PLoS Pathog. 2020;16:e1008921. DOIPubMedGoogle Scholar
  2. Lockhart  SR, Etienne  KA, Vallabhaneni  S, Farooqi  J, Chowdhary  A, Govender  NP, et al. Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64:134–40. DOIPubMedGoogle Scholar
  3. Borman  AM, Johnson  EM. Candida auris in the UK: Introduction, dissemination, and control. PLoS Pathog. 2020;16:e1008563. DOIPubMedGoogle Scholar
  4. Centers for Disease Control and Prevention. 2019 AR threats report. 2021 [cited 2021 Jul 24]. https://www.cdc.gov/drugresistance/biggest-threats.html
  5. Biagi  MJ, Wiederhold  NP, Gibas  C, Wickes  BL, Lozano  V, Bleasdale  SC, et al. Development of high-level Echinocandin resistance in a patient with recurrent Candida auris Candidemia secondary to chronic Candiduria. Open Forum Infect Dis. 2019;6:ofz262. DOIPubMedGoogle Scholar
  6. Ostrowsky  B, Greenko  J, Adams  E, Quinn  M, O’Brien  B, Chaturvedi  V, et al.; C. auris Investigation Work Group. C. auris Investigation Work Group. Candida auris isolates resistant to three classes of antifungal medications—New York, 2019. MMWR Morb Mortal Wkly Rep. 2020;69:6–9. DOIPubMedGoogle Scholar
  7. Ben-Ami  R, Berman  J, Novikov  A, Bash  E, Shachor-Meyouhas  Y, Zakin  S, et al. Multidrug-Resistant Candida haemulonii and C. auris, Tel Aviv, Israel. Emerg Infect Dis. 2017;23:195–203. DOIPubMedGoogle Scholar
  8. Belkin  A, Gazit  Z, Keller  N, Ben-Ami  R, Wieder-Finesod  A, Novikov  A, et al. Candida auris infection leading to nosocomial transmission, Israel, 2017. Emerg Infect Dis. 2018;24:801–4. DOIPubMedGoogle Scholar
  9. Centers for Disease Control and Prevention. Infection prevention and control for Candida auris. 2018 [cited 2018 May 23]. https://www.cdc.gov/fungal/candida-auris/c-auris-infection-control.html
  10. Tsay  S, Kallen  A, Jackson  BR, Chiller  TM, Vallabhaneni  S. Approach to the investigation and management of patients with Candida auris, an emerging multidrug-resistant yeast. Clin Infect Dis. 2018;66:306–11. DOIPubMedGoogle Scholar
  11. Charlson  ME, Pompei  P, Ales  KL, MacKenzie  CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83. DOIPubMedGoogle Scholar
  12. Satoh  K, Makimura  K, Hasumi  Y, Nishiyama  Y, Uchida  K, Yamaguchi  H. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol. 2009;53:41–4. DOIPubMedGoogle Scholar
  13. Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of yeasts: 4th informational supplement (M27–S4). Wayne (PA): The Institute; 2012.
  14. Centers for Disease Control and Prevention. Antifungal susceptibility testing and interpretation. 2020 [cited 2021 Jul 24]. https://www.cdc.gov/fungal/candida-auris/c-auris-antifungal.html
  15. Arendrup  MC, Prakash  A, Meletiadis  J, Sharma  C, Chowdhary  A. Comparison of EUCAST and CLSI reference microdilution MICs of eight antifungal compounds for Candida auris and associated tentative epidemiological cutoff values. Antimicrob Agents Chemother. 2017;61:e00485–17. DOIPubMedGoogle Scholar
  16. Turnidge  J, Kahlmeter  G, Kronvall  G. Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect. 2006;12:418–25. DOIPubMedGoogle Scholar
  17. Kwon  YJ, Shin  JH, Byun  SA, Choi  MJ, Won  EJ, Lee  D, et al. Candida auris clinical isolates from South Korea: identification, antifungal susceptibility, and genotyping. J Clin Microbiol. 2019;57:e01624–18. DOIPubMedGoogle Scholar
  18. Prakash  A, Sharma  C, Singh  A, Kumar Singh  P, Kumar  A, Hagen  F, et al. Evidence of genotypic diversity among Candida auris isolates by multilocus sequence typing, matrix-assisted laser desorption ionization time-of-flight mass spectrometry and amplified fragment length polymorphism. Clin Microbiol Infect. 2016;22:277.e1–9. DOIPubMedGoogle Scholar
  19. Huelsenbeck  JP, Ronquist  F. MRBAYES: Bayesian inference of phylogenetic trees. Bioinformatics. 2001;17:754–5. DOIPubMedGoogle Scholar
  20. Prestel  C, Anderson  E, Forsberg  K, Lyman  M, de Perio  MA, Kuhar  D, et al. Candida auris outbreak in a COVID-19 specialty care unit—Florida, July–August 2020. MMWR Morb Mortal Wkly Rep. 2021;70:56–7. DOIPubMedGoogle Scholar
  21. Rodriguez  JY, Le Pape  P, Lopez  O, Esquea  K, Labiosa  AL, Alvarez-Moreno  C. Candida auris: a latent threat to critically ill patients with coronavirus disease 2019. Clin Infect Dis. 2021;73:e2836–7. DOIPubMedGoogle Scholar
  22. Villanueva-Lozano  H, Treviño-Rangel  RJ, González  GM, Ramírez-Elizondo  MT, Lara-Medrano  R, Aleman-Bocanegra  MC, et al. Outbreak of Candida auris infection in a COVID-19 hospital in Mexico. Clin Microbiol Infect. 2021;27:813–6. DOIPubMedGoogle Scholar
  23. Chowdhary  A, Tarai  B, Singh  A, Sharma  A. Multidrug-resistant Candida auris infections in critically ill coronavirus disease patients, India, April–July 2020. Emerg Infect Dis. 2020;26:2694–6. DOIPubMedGoogle Scholar
  24. Magnasco  L, Mikulska  M, Giacobbe  DR, Taramasso  L, Vena  A, Dentone  C, et al. Spread of carbapenem-resistant gram-negatives and Candida auris during the COVID-19 pandemic in critically ill patients: one step back in antimicrobial stewardship? Microorganisms. 2021;9:95. DOIPubMedGoogle Scholar
  25. Sexton  DJ, Bentz  ML, Welsh  RM, Derado  G, Furin  W, Rose  LJ, et al. Positive correlation between Candida auris skin-colonization burden and environmental contamination at a ventilator-capable skilled nursing facility in Chicago. Clin Infect Dis. 2021;73:1142–8. DOIPubMedGoogle Scholar
  26. Welsh  RM, Bentz  ML, Shams  A, Houston  H, Lyons  A, Rose  LJ, et al. Survival, persistence, and isolation of the emerging multidrug-resistant pathogenic yeast Candida auris on a plastic health care surface. J Clin Microbiol. 2017;55:2996–3005. DOIPubMedGoogle Scholar
  27. Israeli Ministry of Health Medical Division. Management of multidrug resistant organisms of special epidemiological importance in medical facilities [in Hebrew]. 2022 [cited 2023 May 25]. https://www.gov.il/he/departments/policies/mr15-2022

Main Article

1Preliminary results from this study were presented at the 32nd European Congress of Clinical Microbiology and Infectious Diseases, April 23–26, 2022, Lisbon, Portugal.

Page created: April 29, 2023
Page updated: June 20, 2023
Page reviewed: June 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external